AOM 7.13
img385.imageshack.us
AnorMED, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products in the areas of hematology, human immunodeficiency virus (HIV), and oncology. Its products pipeline includes AMD3100, a stem cell mobilizer; AMD070, an HIV entry inhibitor; and programs focused on the discovery of drug candidates that target a specific class of receptors expressed on the surface of immune system cells called chemokine receptors. The company’s other products under development include AMD3100, a stem cell mobilizer for use in cardiac tissue repair; and applications of CXCR4 inhibitors in other indications, including cancer, as well as a research program focused on blocking the CCR5 chemokine receptor as a HIV entry inhibitor. In addition, its additional products portfolio includes FOSRENOL, a drug approved for kidney failure patients to treat hyperphosphataemia; NX473, a cancer chemotherapy agent; Atiprimod, a anticancer agent; and the HYNIC linker, a tool for medical imaging. |
